Market closedADR
Innate Pharma/$IPHA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Ticker
$IPHA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
168
Website
Innate Pharma Metrics
BasicAdvanced
$162M
Market cap
-
P/E ratio
-$0.44
EPS
0.79
Beta
-
Dividend rate
Price and volume
Market cap
$162M
Beta
0.79
52-week high
$3.15
52-week low
$1.29
Average daily volume
935K
Financial strength
Current ratio
2.919
Quick ratio
2.763
Long term debt to equity
92.284
Total debt to equity
123.291
Interest coverage (TTM)
-62.63%
Management effectiveness
Return on assets (TTM)
-13.76%
Return on equity (TTM)
-78.59%
Valuation
Price to revenue (TTM)
6.87
Price to book
5.34
Price to tangible book (TTM)
5.36
Price to free cash flow (TTM)
-11.389
Growth
Revenue change (TTM)
-35.37%
Earnings per share change (TTM)
-46.55%
3-year revenue growth (CAGR)
-9.99%
3-year earnings per share growth (CAGR)
-24.48%
What the Analysts think about Innate Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Innate Pharma stock.
Innate Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Innate Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Innate Pharma News
AllArticlesVideos
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
Business Wire·6 days ago
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
Business Wire·1 week ago
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Innate Pharma stock?
Innate Pharma (IPHA) has a market cap of $162M as of December 15, 2024.
What is the P/E ratio for Innate Pharma stock?
The price to earnings (P/E) ratio for Innate Pharma (IPHA) stock is 0 as of December 15, 2024.
Does Innate Pharma stock pay dividends?
No, Innate Pharma (IPHA) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next Innate Pharma dividend payment date?
Innate Pharma (IPHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Innate Pharma?
Innate Pharma (IPHA) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.